Lumos Diagnostics Holdings Ltd. ( (AU:LDX) ) just unveiled an update.
Lumos Diagnostics reported a revenue of US$3.5 million for the third quarter of FY25, marking a 21% increase from the previous quarter, although down 13% from the same period last year. The company saw significant growth in its services and product revenues, with notable developments including new distribution partnerships for FebriDx® in the U.S. and the expansion of the Hologic fFN project. The company also achieved successful audit results for its quality management system, and FebriDx® was added to the Medicare Fee Schedule, potentially enhancing its market reach.
More about Lumos Diagnostics Holdings Ltd.
Lumos Diagnostics Holdings Ltd. is a leader in rapid point-of-care diagnostic technologies. The company focuses on developing and providing diagnostic tests and custom reader development services, with a market presence in the U.S., Canada, and Australia. Its primary products include FebriDx®, Binx, and ViraDx™, and it maintains ISO 13485:2016 and MDSAP certifications.
YTD Price Performance: -32.50%
Average Trading Volume: 1,454,675
Technical Sentiment Signal: Buy
Current Market Cap: A$20.21M
Find detailed analytics on LDX stock on TipRanks’ Stock Analysis page.